Evidence map›Paper›PMID 32213611›Full record

ArticleJournal of virology2020

Impact of Natural or Synthetic Singletons in the Capsid of Human Bocavirus 1 on Particle Infectivity and Immunoreactivity.

Julia Fakhiri, Kai-Philipp Linse, Mario Mietzsch, Man Xu, Marc A Schneider, Michael Meister, Oliver Schildgen, Paul Schnitzler, Maria Soderlund-Venermo, Mavis Agbandje-McKenna and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Determination of AAV properties by single amino acids: Go(o)d is in the details.Molecular therapy. Methods & clinical development · 2022
    Article
  5. Review
  6. Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Julia Fakhiri *Heidelberg University Hospital, Department of Infectious Diseases/Virology, Heidelberg, Germany.
Kai-Philipp Linse *Heidelberg University Hospital, Department of Infectious Diseases/Virology, Heidelberg, Germany.
Mario MietzschDepartment of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
Man XuDepartment of Virology, University of Helsinki, Helsinki, Finland.
Marc A SchneiderTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Michael MeisterTranslational Research Unit, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany.
Oliver SchildgenInstitute for Pathology, Kliniken der Stadt Köln gGmbH, Hospital of the Private University Witten/Herdecke, Cologne, Germany.ORCID 0000-0003-4297-9627
Paul SchnitzlerHeidelberg University Hospital, Department of Infectious Diseases/Virology, Heidelberg, Germany.
Maria Soderlund-VenermoDepartment of Virology, University of Helsinki, Helsinki, Finland.
Mavis Agbandje-McKennaDepartment of Biochemistry and Molecular Biology, Center for Structural Biology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
Dirk GrimmHeidelberg University Hospital, Department of Infectious Diseases/Virology, Heidelberg, Germany dirk.grimm@bioquant.uni-heidelberg.de.
Heidelberg University · DEUniversity of Florida · USUniversity of Helsinki · FIKliniken der Stadt Köln · DE

Funding

Structural studies of AAV capsids and their glycan receptor interactionsR01GM082946 · NIGMS · UNIVERSITY OF FLORIDA · PI ROBERT MCKENNA · 2007 to 2026
$6.1M
NIGMS NIH HHS R01 GM082946
6 · The paper itself

Abstract

Human bocavirus 1 (HBoV1) is a parvovirus that gathers increasing attention due to its pleiotropic role as a pathogen and emerging vector for human gene therapy. Curiously, albeit a large variety of HBoV1 capsid variants has been isolated from human samples, only one has been studied as a gene transfer vector to date. Here, we analyzed a cohort of HBoV1-positive samples and managed to PCR amplify and sequence 29 distinct HBoV1 capsid variants. These differed from the originally reported HBoV1 reference strain in 32 nucleotides or four amino acids, including a frequent change of threonine to serine at position 590. Interestingly, this T590S mutation was associated with lower viral loads in infected patients. Analysis of the time course of infection in two patients for up to 15 weeks revealed a gradual accumulation of T590S, concurrent with drops in viral loads. Surprisingly, in a recombinant vector context, T590S was beneficial and significantly increased titers compared to that of T590 variants but had no major impact on their transduction ability or immunoreactivity. Additional targeted mutations in the HBoV1 capsid identified several residues that are critical for transduction, capsid assembly, or DNA packaging. Our new findings on the phylogeny, infectivity, and immunoreactivity of HBoV1 capsid variants improve our understanding of bocaviral biology and suggest strategies to enhance HBoV1 gene transfer vectors.

Indexed as

Capsid ProteinsDNA, ViralParvoviridae InfectionsVirus AssemblyCapsidGenetic TherapyGenetic VectorsHEK293 CellsHuman bocavirusHumansTransduction, GeneticCapsid ProteinsDNA, ViralbocavirusBoVcapsidmutations

Identifiers

PMID32213611
PMCPMC7269442
OpenAlexW3013996733

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.